211 related articles for article (PubMed ID: 33571541)
21. Functional and molecular interactions between the HGF/c-Met pathway and c-Myc in large-cell medulloblastoma.
Li Y; Guessous F; Johnson EB; Eberhart CG; Li XN; Shu Q; Fan S; Lal B; Laterra J; Schiff D; Abounader R
Lab Invest; 2008 Feb; 88(2):98-111. PubMed ID: 18059365
[TBL] [Abstract][Full Text] [Related]
22. PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma.
Singh AR; Joshi S; Zulcic M; Alcaraz M; Garlich JR; Morales GA; Cho YJ; Bao L; Levy ML; Newbury R; Malicki D; Messer K; Crawford J; Durden DL
PLoS One; 2016; 11(3):e0150836. PubMed ID: 26938241
[TBL] [Abstract][Full Text] [Related]
23. Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma.
Bolin S; Borgenvik A; Persson CU; Sundström A; Qi J; Bradner JE; Weiss WA; Cho YJ; Weishaupt H; Swartling FJ
Oncogene; 2018 May; 37(21):2850-2862. PubMed ID: 29511348
[TBL] [Abstract][Full Text] [Related]
24. Pharmacological Inhibition of the Protein Kinase MRK/ZAK Radiosensitizes Medulloblastoma.
Markowitz D; Powell C; Tran NL; Berens ME; Ryken TC; Vanan M; Rosen L; He M; Sun S; Symons M; Al-Abed Y; Ruggieri R
Mol Cancer Ther; 2016 Aug; 15(8):1799-808. PubMed ID: 27207779
[TBL] [Abstract][Full Text] [Related]
25. Targeting mTOR as a Therapeutic Approach in Medulloblastoma.
Aldaregia J; Odriozola A; Matheu A; Garcia I
Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29932116
[TBL] [Abstract][Full Text] [Related]
26. Regulatory effects of a Mnk2-eIF4E feedback loop during mTORC1 targeting of human medulloblastoma cells.
Eckerdt F; Beauchamp E; Bell J; Iqbal A; Su B; Fukunaga R; Lulla RR; Goldman S; Platanias LC
Oncotarget; 2014 Sep; 5(18):8442-51. PubMed ID: 25193863
[TBL] [Abstract][Full Text] [Related]
27. RITA displays anti-tumor activity in medulloblastomas independent of TP53 status.
Gottlieb A; Althoff K; Grunewald L; Thor T; Odersky A; Schulte M; Deubzer HE; Heukamp L; Eggert A; Schramm A; Schulte JH; Künkele A
Oncotarget; 2017 Apr; 8(17):27882-27891. PubMed ID: 28427187
[TBL] [Abstract][Full Text] [Related]
28. Molecular and in vivo characterization of cancer-propagating cells derived from MYCN-dependent medulloblastoma.
Ahmad Z; Jasnos L; Gil V; Howell L; Hallsworth A; Petrie K; Sawado T; Chesler L
PLoS One; 2015; 10(3):e0119834. PubMed ID: 25785590
[TBL] [Abstract][Full Text] [Related]
29. c-myc overexpression causes anaplasia in medulloblastoma.
Stearns D; Chaudhry A; Abel TW; Burger PC; Dang CV; Eberhart CG
Cancer Res; 2006 Jan; 66(2):673-81. PubMed ID: 16423996
[TBL] [Abstract][Full Text] [Related]
30. The PI3K inhibitor GDC-0941 displays promising in vitro and in vivo efficacy for targeted medulloblastoma therapy.
Ehrhardt M; Craveiro RB; Holst MI; Pietsch T; Dilloo D
Oncotarget; 2015 Jan; 6(2):802-13. PubMed ID: 25596739
[TBL] [Abstract][Full Text] [Related]
31. Somatic cell transfer of c-Myc and Bcl-2 induces large-cell anaplastic medulloblastomas in mice.
Jenkins NC; Rao G; Eberhart CG; Pedone CA; Dubuc AM; Fults DW
J Neurooncol; 2016 Feb; 126(3):415-24. PubMed ID: 26518543
[TBL] [Abstract][Full Text] [Related]
32. Synergistic activity of mTORC1/2 kinase and MEK inhibitors suppresses pediatric low-grade glioma tumorigenicity and vascularity.
Arnold A; Yuan M; Price A; Harris L; Eberhart CG; Raabe EH
Neuro Oncol; 2020 Apr; 22(4):563-574. PubMed ID: 31841591
[TBL] [Abstract][Full Text] [Related]
33. Molecular regulation of apoptotic machinery and lipid metabolism by mTORC1/mTORC2 dual inhibitors in preclinical models of HER2+/PIK3CAmut breast cancer.
Qian J; Chen Y; Meng T; Ma L; Meng L; Wang X; Yu T; Zask A; Shen J; Yu K
Oncotarget; 2016 Oct; 7(41):67071-67086. PubMed ID: 27563814
[TBL] [Abstract][Full Text] [Related]
34. Novel Glutamine Antagonist JHU395 Suppresses MYC-Driven Medulloblastoma Growth and Induces Apoptosis.
Pham K; Maxwell MJ; Sweeney H; Alt J; Rais R; Eberhart CG; Slusher BS; Raabe EH
J Neuropathol Exp Neurol; 2021 Mar; 80(4):336-344. PubMed ID: 33712838
[TBL] [Abstract][Full Text] [Related]
35. The effect of alpha-v integrin inhibition on the malignant characteristics of medulloblastoma.
Thompson EM; Whitney NL; Wu YJ; Neuwelt EA
J Neurosurg Pediatr; 2013 Jan; 11(1):60-7. PubMed ID: 23082872
[TBL] [Abstract][Full Text] [Related]
36. Combination of Ribociclib with BET-Bromodomain and PI3K/mTOR Inhibitors for Medulloblastoma Treatment In Vitro and In Vivo.
Jonchere B; Williams J; Zindy F; Liu J; Robinson S; Farmer DM; Min J; Yang L; Stripay JL; Wang Y; Freeman BB; Yu J; Shelat AA; Rankovic Z; Roussel MF
Mol Cancer Ther; 2023 Jan; 22(1):37-51. PubMed ID: 36318650
[TBL] [Abstract][Full Text] [Related]
37. Personalizing the treatment of pediatric medulloblastoma: Polo-like kinase 1 as a molecular target in high-risk children.
Triscott J; Lee C; Foster C; Manoranjan B; Pambid MR; Berns R; Fotovati A; Venugopal C; O'Halloran K; Narendran A; Hawkins C; Ramaswamy V; Bouffet E; Taylor MD; Singhal A; Hukin J; Rassekh R; Yip S; Northcott P; Singh SK; Dunham C; Dunn SE
Cancer Res; 2013 Nov; 73(22):6734-44. PubMed ID: 24019381
[TBL] [Abstract][Full Text] [Related]
38. Efficacy, Tolerability, and Pharmacokinetics of Combined Targeted MEK and Dual mTORC1/2 Inhibition in a Preclinical Model of Mucosal Melanoma.
Wei BR; Hoover SB; Peer CJ; Dwyer JE; Adissu HA; Shankarappa P; Yang H; Lee M; Peat TJ; Figg WD; Simpson RM
Mol Cancer Ther; 2020 Nov; 19(11):2308-2318. PubMed ID: 32943547
[TBL] [Abstract][Full Text] [Related]
39. Dual mTORC1/2 Inhibition as a Novel Strategy for the Resensitization and Treatment of Platinum-Resistant Ovarian Cancer.
Musa F; Alard A; David-West G; Curtin JP; Blank SV; Schneider RJ
Mol Cancer Ther; 2016 Jul; 15(7):1557-67. PubMed ID: 27196780
[TBL] [Abstract][Full Text] [Related]
40. Anti-proliferative activity of the quassinoid NBT-272 in childhood medulloblastoma cells.
von Bueren AO; Shalaby T; Rajtarova J; Stearns D; Eberhart CG; Helson L; Arcaro A; Grotzer MA
BMC Cancer; 2007 Jan; 7():19. PubMed ID: 17254356
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
